Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07079020Not Yet Recruiting

Efgartigimod for Consolidation Therapy in gMG

Role: lead

NCT06836973Phase 2Not Yet Recruiting

Blinatumomab for Treatment of Refractory Myasthenia Gravis

Role: lead

NCT04101578Unknown

Clinical Prognosis and Progression of Myasthenia Gravis Patients

Role: lead

NCT04768465Unknown

Tacrolimus Combined With Low-dose Prednisone for Treatment of Myasthenia Gravis

Role: lead

All 4 trials loaded